PHILADELPHIA — Lannett has received approval from the Food and Drug Administration to market its version of an anti-obesity drug.
The FDA approved Lannett's abbreviated new drug application for diethylpropion hydrochloride extended-release tablets in the 75-mg strength. The company expects to begin shipping the product immediately.
